Special Issue

Malignant Adrenal Tumors – from Bench to Bedside

Message from the Guest Editors

Dear colleagues, Malignant adrenal tumors continue to present a challenge in many different ways. As a result of their low incidence, diagnostic delay is always lurking and expertise in the management of malignant adrenal tumors is usually not widely available. Adding to the complexity, malignant adrenal tumors have different origins (i.e. adrenal cortex, adrenal medulla, metastasis of extra-adrenal malignancy) and are highly heterogeneous in their clinical presentation and biological behavior. Radiological and pathological differentiation of malignant from benign adrenal tumors can be very difficult. In addition, there is an unmet need for new medical treatment modalities. In recent years. however, both basic and clinical research have produced much relevant and exciting new information on these disorders. The improved understanding of malignant adrenal tumors has either translated into changes in the clinical management or has revealed new characteristics or pathways which may ultimately provide novel diagnostic techniques or therapeutic options.

Guest Editors

Dr. Richard A. Feelders

Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

Dr. Michiel N. Kerstens

Department of Endocrinology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

Deadline for manuscript submissions

closed (1 August 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/65081

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

